Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06609226 |
| Consolidated Lead Sponsor | Novo Nordisk |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 480 participants (ESTIMATED) |
| Registered Start Date | 2025-01-10 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Children's Hospital Los Angeles | Los Angeles, CA | Open Hospital Dossier -> |
| UCI Health and Chao Family Comprehensive Cancer Center | Orange, CA | Open Hospital Dossier -> |
| Children's National Medical Center | Washington D.C, DC | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.